血脂康与普伐他汀对血脂正常冠心病患者脂联素及肿瘤坏死因子水平影响的对比研究  

The Change of Adiponectin and Tumour Necrosis Factor-αin Patients with Coronary Heart Disease and Influence of Xuezhikang and Pravastatin Therapy

作　　者：赵红丽[1] 李潞[1] 刘丽敏[1] 李纯[1] 张晓丹[1] 王晓昕[1] 

机构地区：[1]沈阳医学院附属沈洲医院心内科,沈阳110002

出　　处：《中国医药导刊》2008年第1期113-115,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:比较血脂康与普伐他汀对血脂正常冠心病患者血清脂联素及肿瘤坏死因子水平的影响。方法:入选80例血脂正常冠心病患者随机分为血脂康组和普伐他汀组,血脂康组给予血脂康0.6日二次口服,普伐他汀组给予普伐他汀40mg日一次口服,在用药前及用药12周后分别测定血清脂联素及肿瘤坏死因子水平。结果:在用药后,血脂康降低血清低密度脂蛋白胆固醇(LDL-C)与总胆固醇(TC)作用与普伐他汀相似(>0.05);血脂康组与普伐他汀组血清脂联素水平均明显增高及肿瘤坏死因子水平明显降低,两组间差异无统计学意义(P>0.05)。结论:血脂康可使血脂正常冠心病患者脂联素水平升高及肿瘤坏死因子水平降低,其作用等同于普伐他汀。Objective： To investigate the change of adiponectin and tumour necrosis factor-α（TNF-α）in patients with coronary heart disease and influence of Xuezhikang and pravastatin therapy. Methods： A total of 80 patients in coronary heart disease with normal cholesterolemia were selected and randomly to Xuezhikang group and pravastatin group . Xuezhikang was given 0.6 Bid po. pravastatin was given 40mg Qd po. adiponectin and TNF-α of all patients were analyzed at baseline, 12 weeks after given Xuezhikang and pravastatin in trail patients, Results： The levels of adiponectin and TNF-α between Xuezhikang group and pravastatin group were no difference after given drugs 12 weeks（P〉0.05） ,The levels of cholesterolemia in two groups were depress as well（P〉0.05）. Conclusion.. The levels of adiponectin were higer and TNF-a significantly lower in patients with coronary heart disease if given Xuezhikang.

关 键 词：冠心病 脂联素 肿瘤坏死因子 血脂康 

分 类 号：R541.4[医药卫生—心血管疾病]